How is primary mantle cell lymphoma (MCL) treated?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Reliably curative treatments for MCL are lacking. An inexorable pattern of progression is characteristic, with a median time to treatment failure of less than 18 months. Primary MCL therapy may consist of the following:

  • Single alkylating agents (eg, chlorambucil)

  • Cyclophosphamide, doxorubicin (Hydrodaunorubicin), vincristine (Oncovin), and prednisone (CHOP)

  • Cyclophosphamide, vincristine, and prednisone (CVP)

  • Hyperfractionated cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone (hyper-CVAD)

  • Bortezomib (Velcade), rituximab, cyclophosphamide, doxorubicin, and prednisone

  • CHOP plus rituximab (R-CHOP)

  • Hyper-CVAD with autologous stem cell transplantation (ASCT)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!